JAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib
DOI:
https://doi.org/10.2340/actadv.v105.44081Keywords:
down syndrome, alopecia areata, vitiligo, Jak inhibitor, BaricitinibDownloads
References
Hom B, Boyd NK, Vogel BN, Nishimori N, Khoshnood MM, Jafarpour S, et al. Down syndrome and autoimmune disease. Clin Rev Allergy Immunol 2024; 66: 261–273. DOI: https://doi.org/10.1007/s12016-024-08996-2
Waugh KA, Araya P, Pandey A, Jordan KR, Smith KP, Granrath RE, et al. Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in Down syndrome. Cell Rep 2019; 29: 1893–1908.e4. DOI: https://doi.org/10.1016/j.celrep.2019.10.038
Waugh KA, Minter R, Baxter J, Chi C, Galbraith MD, Tuttle KD, et al. Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. Nat Genet 2023; 55: 1034–1047. DOI: https://doi.org/10.1038/s41588-023-01399-7
Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol 2021; 61: 403–423. DOI: https://doi.org/10.1007/s12016-021-08883-0
Rork JF, McCormack L, Lal K, Wiss K, Belazarian L. Dermatologic conditions in Down syndrome: a single-center retrospective chart review. Pediatr Dermatol 2020; 37: 811–816. DOI: https://doi.org/10.1111/pde.14214
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386: 1687–1699. DOI: https://doi.org/10.1056/NEJMoa2110343
Sáenz LM, Villarreal JDM. Unlocking the potential of baricitinib for vitiligo. Cutis 2024; 114: 95–96. DOI: https://doi.org/10.12788/cutis.1093
Rachubinski AL, Wallace E, Gurnee E, Enriquez-Estrada BA, Worek KR, Smith KP, et al. JAK inhibition decreases the autoimmune burden in Down syndrome. eLife 2024; 13: RP99323. DOI: https://doi.org/10.7554/eLife.99323
Galbraith MD, Rachubinski AL, Smith KP, Araya P, Waugh KA, Enriquez-Estrada B, et al. Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition. Sci Adv 2023; 9: eadg6218. DOI: https://doi.org/10.1126/sciadv.adg6218
Yamaguchi HL, Yamaguchi Y, Peeva E. Pathogenesis of alopecia areata and vitiligo: commonalities and differences. Int J Mol Sci 2024; 25: 4409. DOI: https://doi.org/10.3390/ijms25084409
Rachubinski AL, Estrada BE, Norris D, Dunnick CA, Boldrick JC, Espinosa JM. Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata. JAAD Case Rep 2019; 5: 365–367. DOI: https://doi.org/10.1016/j.jdcr.2019.02.007
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol 2017; 77: 675–682.e1. DOI: https://doi.org/10.1016/j.jaad.2017.05.043
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Federica Li Pomi, Mario Vaccaro, Marta Vitale, Roberta Alaimo, Francesco Borgia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
